FY2025 Earnings Estimate for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Analysts at William Blair issued their FY2025 EPS estimates for shares of Immunic in a report released on Monday, March 24th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.89) for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share.

Several other brokerages have also commented on IMUX. StockNews.com lowered shares of Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Immunic in a research report on Friday, February 21st. Finally, D. Boral Capital reissued a "buy" rating and issued a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $12.67.

Immunic Price Performance

Shares of IMUX traded down $0.04 during mid-day trading on Wednesday, reaching $1.20. The company's stock had a trading volume of 653,857 shares, compared to its average volume of 604,174. The company's 50 day moving average is $1.08 and its 200 day moving average is $1.21. The stock has a market cap of $108.09 million, a PE ratio of -0.98 and a beta of 1.89. Immunic has a 12-month low of $0.92 and a 12-month high of $2.11.

Remove Ads

Institutional Investors Weigh In On Immunic

Several hedge funds have recently made changes to their positions in IMUX. Focus Partners Wealth raised its stake in shares of Immunic by 1.1% during the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock worth $2,168,000 after purchasing an additional 23,610 shares during the last quarter. 683 Capital Management LLC raised its holdings in Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock worth $700,000 after purchasing an additional 15,349 shares in the last quarter. Millennium Management LLC lifted its position in Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after buying an additional 177,542 shares during the period. Finally, Bridgeway Capital Management LLC grew its stake in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock worth $215,000 after purchasing an additional 22,200 shares during the period. Institutional investors and hedge funds own 51.82% of the company's stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.